EMA recommends Baxalta cancer drug; U.K.'s NHS speeds new cancer treatments to patients;

@FiercePharma: Price controls loom for generic drugs in India next year. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Report | Follow @EricPFierce

> The EMA has recommended approval of Baxalta's ($BXLT) Oncaspar; Baxter ($BAX) bought the cancer drug from Italy's Sigma-Tau Finanziaria for $900 million ahead of spinning Baxalta off this summer. Release

> South Africa's Ascendis Health has bought a competitor for $25 million. Story

> The EMA has recommended approval of a new treatment for narcolepsy. Release

> The U.K.'s National Health System is trying to speed the process of getting new cancer treatments to patients. Report

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: St. Jude earns FDA approval for recharge-free spinal cord stimulation system. Article | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Bard to buy Liberator for $181M to improve access to home care market. Article

> Cancer diagnostics company closes up shop after 6-year FTC investigation. More

> Philips launches smartphone plug-in ultrasound handheld with app in U.S. Story

Biotech News

@FierceBiotech: TEDMED 2015: A brief history of CRISPR and what's next. Article | Follow @FierceBiotech

@JohnCFierce: To me, the FDA review of drisa reads like a letter to DMD parents. You don't want this drug. Please don't be angry.  | Follow @JohnCFierce

@DamianFierce: "Did you name me after the mayor of New York, dad?" "Yes, Kristaps, but he was just a basketball player then." | Follow @DamianFierce

> FDA takes a dim view of BioMarin's DMD drug, citing 'contradictory' data. Story

> Samsung and Biogen verge on EU approval with an Enbrel biosimilar. Report

> AstraZeneca, Sanofi swap 210,000 compounds in no-cash deal. Article